Alvotech Shares Rise After FDA Approves Additional Manufacturing for Simlandi
Alvotech shares rose after the company said the Food and Drug Administration has approved a supplement to the biologics license application for AVT02 adalimumab-ryvk, marketed in the U.S. as Simlandi.
Alvotech shares rose after the company said the Food and Drug Administration approved a supplement to the biologics license application for AVT02 adalimumab-ryvk, which is marketed in the U.S. as Simlandi. The stock was 13% higher, at $6.18, in midday trade, but is 26% lower in the past 12 m…